DP VPA

Drug Profile

DP VPA

Alternative Names: DP-VPA; SPD 421

Latest Information Update: 16 Dec 2015

Price : $50

At a glance

  • Originator D-Pharm
  • Class Antiepileptic drugs; Neuroprotectants; Pentanoic acids
  • Mechanism of Action GABA uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Epilepsy
  • Phase I Bipolar disorders; Migraine

Most Recent Events

  • 16 Dec 2015 Phase-II development is ongoing for Epilepsy and phase I development is ongoing for Migraine and Bipolar disorders, in Israel
  • 14 Apr 2015 The Chinese Food and Drug Administration approves IND application for DP VPA in Epilepsy
  • 07 Nov 2014 Phase-II development is ongoing for Epilepsy and phase I development is ongoing for Migraine and Bipolar disorders, in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top